Double blind

3 trials

Sponsors

Roche Nederland B.V., AbbVie, Novartis Pharma AG

Conditions

Artritis Psoriatica psoriatic arthritisAsthma Severe corticosteroid dependent Asthmaasthma chronic lung inflammation

Phase 2

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID*SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA.

Active, not recruitingNL-OMON42207

Roche Nederland B.V.Asthma Severe corticosteroid dependent Asthma

Start: 2015-09-09Target: 15Updated: 2024-02-28

A randomized, double-blind, double-dummy, activecontrolled, 3-period complete cross-over study to assess the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combination of salmeterol/fluticasone in patients with asthma.

Active, not recruitingNL-OMON47676

Novartis Pharma AGasthma chronic lung inflammation

Start: 2017-05-31Target: 10Updated: 2024-02-28

Phase 3

A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2

Active, not recruitingNL-OMON45660

AbbVieArtritis Psoriatica psoriatic arthritis

Start: 2018-07-17Target: 20Updated: 2024-02-28